James Cusack, MD
James Cusack, MD
Director, Peritoneal Surface Malignancy Program (HIPEC)
Director, Global Surgery Initiative
Departments, Centers, & Programs:
Mass General Surgery: Surgical Oncology
55 Fruit St.
Yawkey Center for Outpatient Care
Boston, MA 02114
- MD, Emory University
- Residency, Tufts Medical Center
- Fellowship, University of Texas - MD Anderson Cancer Center
American Board Certifications
- Surgery, American Board of Surgery
Accepted Insurance Plans
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
The Cusack Laboratory has made landmark contributions to the field of molecular therapeutics, advancing the understanding of chemotherapy resistance within cancer cells. Dr. Cusack is Director of the Surgical Oncology Laboratories at the Massachusetts General Hospital. His two most cited papers in Nature Medicine 1999 and Cancer Research 2001 describe the inhibition of the transcription factor NF-kappaB to overcome inducible chemotherapy resistance. Dr. Cusack is co-inventor of the patent that describes this therapeutic strategy, now licensed to two pharmaceutical companies for drug development. He recently defined the role of HB-EGF, a downstream target of NF-kappaB in cancer resistance. Based on this work, he developed a new cancer treatment with scientists in Japan. Ongoing areas of investigation include the development of targeted therapeutic approaches to overcome resistance mechanisms in melanoma, rectal cancer, and Merkel Cell carcinoma. His bibliography lists over 70 publications, and he continues to serve on numerous editorial boards. Dr. Cusack's laboratory has been funded since 1995 by the National Institutes of Health, the American Cancer Society, biotech collaborators, and his patients.
If you would like to make a contribution to the Cusack Laboratory, please call 617-726-1691.
- Chan CHF, Cusack, JC, Ryan DP. A critical look at local-regional management of peritoneal metastasis. Hem Onc Clinics N Am 2015 Feb; 29 (1):153-58.
- Cercek A, MD, Cusack JC, Ryan DP. Treatment of Peritoneal Carcinomatosis of Colorectal Origin. Am Soc Clin Oncol Educ Book. 2015; 35:e208-11.
- Chao TE, Riesel J, Anderson G, Mullen JT, Doyle J, Briggs S, Lillemoe KD, Goldstein C, Kitya D, Cusack JC. Building a Global Surgery Initiative Through Evaluation, Collaboration, and Training: The Massachusetts General Hospital Experience. J Surg Educ. 2015 Jul-Aug; 72(4):e21-8.
- Santamaria-Barria J, Boland G, Yeap BY, Nardi V, Dias-Santagata D, Cusack JC. Merkel Cell Carcinoma: 30-year experience from a single institution. Ann Surg Onc 2013;20(4):1365-73..
- Chan CH, Liesenfeld LF, Ferreiro-Neira I, Cusack JC Jr. Preclinical evaluation of Cathepsin-based fluorescent imaging system for cytoreductive surgery. Ann Surg Oncol. 2017 Apr;24(4):931-938.
- Yozu M, Johncilla M, Srivastava A, Ryan DP, Cusack JC, Doyle L, Setia N, Yang M, Lauwers G, Odze R, Misdraji J. Histologic and Outcome Study Supports Reclassifying Appendiceal Goblet Cell Carcinoids as Goblet Cell Adenocarcinomas, and Grading and Staging Similar to Colonic Adenocarcinomas. Am J Surg Pathol. 2018 Jul; 42(7): 898-910.
- Chawla A, Zhu C, Backer G, O'Gara J, Fong Z, Deng H, Bao X, Cusack J. Perioperative management of patients undergoing CRS and HIPEC. Clinics in Surgery. March 2020; 5: article 2788 pp1-7.
- Chicago Consensus Working Group. The Chicago Consensus Guidelines for Peritoneal Surface Malignancies: Introduction. Ann Surg Oncol. 2020 Jun; 27(6)1737-40.